glp-1 agonists and sglt2 inhibitors Combining Receptor in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy SGLT2 Inhibitors vs. GLP-1 Agonists

This is particularly evident in specific cardiovascular conditions such as heart failure with preserved ejection fraction (HFpEF), for which effective treatments are scarce

Kim S, Moon M, Park S

Hair loss (4%) 5

A phenomenon known as symptom turnover is seen in those experiencing GI symptoms where individual symptoms appear or disappear over time, while the overall prevalence in a given population may remain stable

Clinical Trials and Safety Profile: In 2006, dipeptidyl-peptidase-4 (DPP-4) inhibitors were launched for the treatment of type 2 diabetes

These are signs that the glucagon component is driving energy expenditure at a level that meaningfully contributes to the overall weight loss beyond what GLP-1 and GIP provide alone